Aytu Biopharma, INC 10-Q quarterly reports

Aytu BioPharma reported a 33% revenue decline in Q3 2026, primarily due to a strategic shift from ADHD products to EXXUA, with the new drug's launch partially offsetting the decrease.

Aytu BioPharma reported a significant net loss for the second fiscal quarter and first half of 2026, driven by derivative warrant liabilities and a strategic pivot towards its newly launched antidepressant, EXXUA, while divesting non-core assets.

Aytu BioPharma reports a net income of $1.965 million for Q1 fiscal 2026, driven by a derivative warrant liabilities gain, as it prepares for the anticipated launch of its major depressive disorder treatment, EXXUA.

Aytu BioPharma reports a profitable third quarter in fiscal year 2025, driven by revenue growth in its ADHD and Pediatric portfolios and effective cost management.

Aytu BioPharma's Q2 2025 results reveal a revenue decrease due to payer changes and competitor activity, alongside strategic efforts to streamline operations and manage costs.

Aytu BioPharma's Q1 2025 results show a net income of $1.474 million, driven by the ADHD portfolio and a strategic divestiture, despite a slight decrease in overall revenue.

Aytu BioPharma's Q3 2024 results show a decrease in revenue and a net loss, raising concerns about the company's ability to continue as a going concern.

Aytu BioPharma's Q2 results show a decrease in revenue, primarily due to the wind-down of the Consumer Health segment, alongside a strategic focus on its Rx business.